Cancer Biomarkers Funding Opportunities
| Title | Announcement # |
Expiration Date |
|---|---|---|
| Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection | PAR-16-276 (R01) | 06/14/2019 |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research | RFA-CA-19-019 (R21 Clinical Trials Not Allowed) | 09/28/2019 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research | RFA-CA-19-021 (R21 Clinical Trials Not Allowed) | 09/28/2019 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research | RFA-CA-19-022 (R33 Clinical Trials Not Allowed) | 09/28/2019 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research | RFA-CA-19-020 (R33 Clinical Trials Not Allowed) | 09/28/2019 |
| Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems | PAR-18-009 (R01 Clinical Trial Optional) | 11/06/2019 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 - Clinical Trials Not Allowed) | PAR-18-317 | 10/09/2020 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed | PAR-18-310 | 10/09/2020 |
| Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine | PAR-18-841 (U24 - Clinical Trial Optional) | 06/15/2021 |
| Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research | PA-18-902 (R01 Clinical Trial Optional) | 09/08/2021 |
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-252 (R21 Clinical Trial Optional) | 11/09/2021 |
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-251 (R01 Clinical Trial Optional) | 11/09/2021 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-19-113 (R01 Clinical Trial Optional) | 01/08/2022 |